Dulaglutide

Label FDA-approved

ClassGLP-1 RA

Typical routes in papersWeekly SC (pen)

Half-life context~5 days

EvidenceFDA-approved

What it is

Dulaglutide is weekly GLP-1 (Trulicity) for type 2 diabetes, with cardiovascular-outcome data on the brand.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

Same family benefits as other GLP-1s: appetite down, glucose down, some weight change.
The device is a ready-to-use weekly pen on the approved product — not a compounded mystery dose.
Choose this monograph when comparing weeklies (sema, dulaglutide, tirzepatide).

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

GLP-1 receptor agonism with an IgG4-Fc fusion that extends half-life to weekly.

Possible side effects / caveats

GI titration effects, class warnings (pancreatitis language, boxed thyroid C-cell warning in rodents).

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Label	0.75 mg weekly, may rise to 1.5, 3.0, or 4.5 mg	Weekly SC	Diabetes insert; confirm current

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.